Skip to main content

Table 1 Demographic and treatment characteristics of study participants

From: Reduced IgM levels and elevated IgG levels against oxidized low-density lipoproteins in HIV-1 infection

  Subject group
  CD4 < 250 CD4 > 500 ART (PI/r) ART (NNRTI) HIV- p-value
  n = 22 n = 22 n = 24 n = 23 n = 92
Sex (male:female) 12:10 16:6 11:13 18:5 56:36 ns
Age in years 36 (22–61) 45 (20–73) 41 (21–65) 46 (27–62) 44 (20–73) ns
Months since HIV-diagnosis 0 (0–101) 30 (3–207) 152 (32–305) 155 (50–302) ***
CD4 nadir (× 106 cells/l) 170 (30–250) 480 (300–1000) 175 (0–310) 150 (0–470) ***
CD4 at baseline (× 106 cells/l) 170 (40–250) 605 (520–1000) 565 (360–1100) 470 (270–900) ***
HIV RNA (log10 copies/ml) 4.89 (2.89–5.93) 3.87 (< 1.28–5.12) All < 1.28 All < 1.28 ***
Pre-ART HIV RNA (log10 copies/ml) 5.05 (2.63–6.62) 4.88 (2.92–5.79) **
Treatment duration (months) 57 (28–204) 77 (28–210) ns
Apolipoprotein B (g/L) 0.81 (0.47–1.40) 0.92 (0.47–1.40) 1.10 (0.33–1.50) 1.00 (0.47–1.80) 0.87 (0.42–2.20) *
Apolipoprotein A1 (g/L) 1.40 (0.76–2.10) 1.45 (0.94–1.90) 1.55 (1.10–1.90) 1.70 (1.10–2.80) 1.50 (1.10–2.60) ns
Total cholesterol (mmol/L) 4.2 (3.0–8.4) 5.0 (3.6–7.1) 5.7 (2.4–7.8) 6.0 (3.6–9.5) ***
HDL-cholesterol (mmol/L) 1.3 (0.6–2.1) 1.3 (0.6–2.1) 1.2 (0.9–2.0) 1.5 (0.9–2.7) ns
Triglycerides (mmol/L) 1.20 (0.49–4.30) 1.45 (0.50–2.50) 2.15 (0.78–9.40) 1.70 (0.71–12.00) **
hsCRP (mg/L) 2.75 (0.17–50.00) 1.60 (0.00–12.00) 1.40 (0.00–14.00) 3.50 (0.34–11.00) 0.63 (0.0–36.00) ***
Soluble CD14 (ng/mL) 1333 (991–3762) 1491 (842–1888) 1621 (1067–2283) 1796 (1228–3528) 1259 (872–2131) ***
  1. Significance testing was performed for all five groups where data was available for HIV- controls, otherwise only for HIV + subjects. ART: antiretroviral treament; PI/r: ritonavir-boosted protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; hsCRP: highly sensitivity C-reactive protein. All values are given as median (range). NS: not significant; *p < 0.05; **p < 0.01; ***p < 0.001.
\